Therapeutic Research

Abstract

It is considered that the disorder of cholesterol metabolism and an inflammatory response are associated with cardiovascular risk. In order to prevent cardiovascular disease, a strict control of cholesterol level and suppression of inflammatory response should be needed. The aim of this study is to evaluate the risk reducing effects of fluvastatin at increasing daily dose from 20 mg to 30 mg in patients with dyslipidemia. During the treatment with fluvastatin 20 mg and 6 months after the treatment with fluvastatin 30 mg, lipid profiles, high−sensitive CRP（hs−CRP）as a inflammatory parameter and ankle−brachial PWV （baPWV）were measured. In 37 patients, LDL cholesterol and hs−CRP were significantly decreased from 134±33 mg／dL to 116±29 mg／dL（p＜0.001）and from 0.086±0.066 mg／dL to 0.071±0.048 mg／dL（p＝0.016）, respectively. The baPWV was also decreased from 1743±384 cm／sec to 1659±335 cm／sec（p＜0.016）. Changes in blood pressure and heart rate were not significantly. The dose increasing treatment with fluvastatin 20 mg to 30 mg may be more potent on cholesterol lowering and anti−inflammatory effects for patients with dyslipidemia.